|
Re: Japanese Cucumber for - Chronic PKD pain
|
Diane Smith
|
Nov 03, 2009 16:42 PST
|
--Apple-Mail-79--184793828
Content-Transfer-Encoding: 8bit
Content-Type: text/plain;
charset=iso-8859-1;
format=flowed;
delsp=yes
Here is a picture of a Japanese cucumber
On Nov 3, 2009, at 6:42 AM, Tzee Ky wrote:
| | My opinion:
I eat Japanese cucumber at lease one per day. It helps me to avoid
liver cyst Symptoms (pain, heat, itch, swollen, and uncomfortable)
in my liver cyst. Japanese cucumber really works for me. My symptom
starts from November every year. I went to see my doctor and he
referred me to an expert. It did not help at all. Finally, I found
the solution - Japaneses cucumber. I see no doctor from that on.
I hope it works for you.
Best Regards,
Tzee Ky
From: "jcro-@aol.com" <jcro-@aol.com>
To: pk-@topica.com
Sent: Tue, November 3, 2009 6:41:54 AM
Subject: Re: PKD-PLD Chronic PKD pain
Dear Diane,
At the beginning of my journey with PKD some 14 years ago, I had a
lot of cyst ruptures, excruciating pain that would leave me
bedridden for days. I was 28 years old. Then, I started reading
and searching until I learned about you, the diets and how to change
my diet to improve things. Although, I am not 100% vegetarian, I
did changed many items of my diet and added some others. I can
honestly say that I have not had any pain episodes in years. I
can't tell you when was the last time because I truly do not remember.
Both my natives are larger than they were then but I do not have not
had any more ruptures or pain. I think for me the secret has been:
no red meats, no artificial foods. I also drink nothing but natural
juices and water. I do not drink sodas, whole milk or alcohol and I
drink a tall glass of cranberry juice every single morning and some
afternoons for the last 14 years.
BTW...I am reading The China Project. What an amazing and
interesting book. You are living proof that what they found does
work. I can wait to finish reading it.
Rgds,
JC
In a message dated 10/29/2009 7:40:33 P.M. Eastern Standard Time, Dia-@pkdiet.com
writes:
I understand what you are saying JC. Many many years ago, in my
hippy days, I traveled extensively throughout Asia, it was so sad to
meet up with fellow travelers later after they had become addicted
to opium or heroin. They were like walking skeletons.
Opiates happen to be something I cannot take. I just throw up and
cannot keep it down. Following my liver resection surgery the docs
got very creative on what to give me to relieve pain.
There are several with PKD who have written to me that the only way
they can function is by taking opiates to control the daily chronic
pain from PKD.
By removing a cystic PKD kidney this has been shown to lessen
painful episodes. A very observant surgeon developed a denervation
procedure of PKD kidneys as another treatment to lessen severe PKD
pain.
There is a PKD pain study underway at the Mayo Clinic with Dr. Marie
Hogan that utilizes an interventional procedure known as -
Videothracoscopic Splanchnicectomy (VSPL) similar to
Videothoracoscopic splanchnicectomy done for pancreatitis pain. For
more information on this clinical trial :
http://www.pkdiet.com/pages/pain/painchronic.htm
I too did not realize how difficult and how severe PKD pain can
become with some individuals until I went to PKD conference and met
with a few individuals using fentanyl patches and more to function.
"FDA announced on February 12, 2008, that PriCara, Division of Ortho-
McNeil-Janssen Pharmaceuticals, Inc.has recalled all lots of 25 mcg
DURAGESIC® (fentanyl transdermal system) patches sold by PriCara in
the United States and all 25 mcg/hr fentanyl patches sold by Sandoz
Inc.(See:Sandoz Fentanyl Patch Recall) in the United States are
being voluntarily recalled."
At this same PKD conference there was a PKD pain lecture given by
both Dr. Torres [giving the medical aspects of PKD pain relief] and
the laparoscopic surgeon who developed the denervation procedure. I
always learn so much from these conferences, though I have not gone
to one since Dr. Torres stopped going.
Warmly,
Diane
<Diane1.jpg>
On Oct 29, 2009, at 12:23 PM, jcro-@aol.com wrote:
| | I refused to take Opiates at all cost. Part of my work is working
with drug addicted patients and I have seen what Opiates do to a
persons life. It literally destroys them physically, financially,
mentally and emotionally to the point that they can not function.
It is very sad. Do not take them if you can help it. They are
extremely addictive.
Rgds,
JC
In a message dated 10/29/2009 2:40:55 P.M. Eastern Daylight Time, Dia-@pkdiet.com
writes:
Some members have chronic pain from PLD and take opiods which can
lead to constipation. Here is a new drug to ask your docs about if
this applys to you.
ACG: Compound Eases Constipation for Opioid Patients
By Kristina Fiore, Staff Writer, MedPage Today
Published: October 28, 2009
Reviewed by Zalman S. Agus, MD; Emeritus Professor
University of Pennsylvania School of Medicine and
Dorothy Caputo, MA, RN, BC-ADM, CDE, Nurse Planner
<16658.jpg>
SAN DIEGO -- An investigational drug increased spontaneous bowel
movements for patients with opioid-induced constipation,
researchers said here.
Bowel movements per week increased from about one at baseline to
five or six, depending on the dose used, Lynn Webster, MD, of
Lifetree Clinical Research in Salt Lake City, and colleagues
reported at the American College of Gastroenterology meeting here.
The drug, NKTR-118, "increased the frequency of bowel movements
without a reversal of analgesia, and it was reasonably safe with no
serious problems in this study," Webster said.
He said constipation is a common side effect of opioid therapy,
affecting about 40% to 60% of patients on chronic or acute
treatments.
The investigational compound is a polymer form of naloxone that
antag onizes peripheral opioid receptors in the gut. It can act
selectively, preventing it from reversing opioid pain management,
the researchers said.
For their Phase-II, randomized, double-blind, placebo-controlled
trial, the researchers recruited patients on stable regimens of
opioids who consistently had fewer than three spontaneous bowel
movements per week.
A total of 208 patients were randomized to either a 5-mg, 25-mg, or
50-mg dose of NKTR-118 or placebo for four weeks.
The researchers found that spontaneous bowel movements increased
significantly for patients on the 25-mg and 50-mg dose compared
with placebo.
Patients on the 25-mg dose increased to five spontaneous bowel
movements per week, up from 1.4 per week at baseline, whereas
placebo patients increased to just 3.1 per week from 1.2 at baseline.
Those on the 50-mg dose had six spontaneous bowel movements per
week, up from 1.6 at baseline -- a significant improvement compared
with those on placebo, who increased to 3.3 per week from 1.4 at
baseline.
Spontaneous bowel movements for patients on the 5-mg dose did not
differ significantly from those on placebo, the researchers said.
The median time to first bowel movement was 6.6 hours for those in
the 25-mg dose, compared with 48.6 hours for those on placebo
(P=0.001). It was 2.9 hours for those on the 50-mg dose, compared
with 44.9 hours with placebo (P=0.002).
Webster said that there was no change in patient pain, and there
were no changes in the amount of opioid used for any patient.
However, dropout rates were significantly higher for the 50-mg dose
of the drug compared with placebo, "probably due to the side effect
profile," Webster said.
The most sign ificant side effects associated with the drug were
gastrointestinal in nature, and included nausea and abdominal pain.
Side effects were not significantly different for the 5-mg dose
compared with placebo, and there was more nausea in the placebo
group for the 25-mg dose, but side effects were significantly
higher in the 50-mg dose compared with placebo.
There was also one serious adverse event in the 50-mg dose, with a
patient admitted to the hospital for excessive abdominal cramping.
|
|
--Apple-Mail-79--184793828
Content-Type: multipart/related;
type="text/html";
boundary=Apple-Mail-80--184793828
--Apple-Mail-80--184793828
Content-Transfer-Encoding: 8bit
Content-Type: text/html;
charset=iso-8859-1
<html><head><base href="x-msg://42/"></head><body style="word-wrap: break-word; -webkit-nbsp-mode: space; -webkit-line-break: after-white-space; ">Here is a picture of a Japanese cucumber<div><br></div><div><img height="38" width="50" apple-width="yes" apple-height="yes" id="bb792f35-02dc-4837-a888-e25355385253" src="cid:4C0F4049-ABDD-44D2-@hawaii.rr.com"><br><div><div>On Nov 3, 2009, at 6:42 AM, Tzee Ky wrote:</div><br class="Apple-interchange-newline"><blockquote type="cite"><div><div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; font-family: 'times new roman', 'new york', times, serif; font-size: 12pt; "><div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; ">My opinion:</div><div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; "> </div><div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; ">I eat Japanese cucumber at lease one per day. It helps me to avoid liver cyst<span class="Apple-converted-space"> </span><span style="font-size: 11pt; line-height: 17px; font-family: Calibri, sans-serif; ">Symptoms</span><span class="Apple-converted-space"> </span>(pain, heat, itch, swollen, and uncomfortable) in my liver cyst. Japanese cucumber really works for me. My symptom starts from November every year. I went to see my doctor and he referred me to an expert. It did not help at all. Finally, I found the solution - Japaneses cucumber. I see no doctor from that on.</div><div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; "> </div><div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; ">I hope it works for you.</div><div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; "> </div><div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; ">Best Regards,</div><div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; "> </div><div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; ">Tzee Ky</div><div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; "><br> </div><div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; font-size: 12pt; font-family: 'times new roman', 'new york', times, serif; "><br><div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; font-size: 12pt; font-family: 'times new roman', 'new york', times, serif; "><font face="Tahoma" size="2"><hr size="1"><b><span style="font-weight: bold; ">From:</span></b><span class="Apple-converted-space"> </span>"<a href="mailto:jcro-@aol.com">jcro-@aol.com</a>" <<a href="mailto:jcro-@aol.com">jcro-@aol.com</a>><br><b><span style="font-weight: bold; ">To:</span></b><span class="Apple-converted-space"> </span><a href="mailto:pk-@topica.com">pk-@topica.com</a><br><b><span style="font-weight: bold; ">Sent:</span></b><span class="Apple-converted-space"> </span>Tue, November 3, 2009 6:41:54 AM<br><b><span style="font-weight: bold; ">Subject:</span></b><span class="Apple-converted-space"> </span>Re: PKD-PLD Chronic PKD pain<br></font><br><font id="role_document" face="Arial" color="#000000" size="2"><div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; "><div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; ">Dear Diane,</div><div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; "> </div><div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; ">At the beginning of my journey with PKD some 14 years ago, I had a lot of cyst ruptures, excruciating pain that would leave me bedridden for days. I was 28 years old. Then, I started reading and searching until I learned about you, the diets and how to change my diet to improve things. Although, I am not 100% vegetarian, I did changed many items of my diet and added some others. I can honestly say that I have not had any pain episodes in years. I can't tell you when was the last time because I truly do not remember.</div><div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; "> </div><div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; ">Both my natives are larger than they were then but I do not have not had any more ruptures or pain. I think for me the secret has been: no red meats, no artificial foods. I also drink nothing but natural juices and water. I do not drink sodas, whole milk or alcohol and I drink a tall glass of cranberry juice every single morning and some afternoons for the last 14 years.</div><div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; "> </div><div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; ">BTW...I am reading The China Project. What an amazing and interesting book. You are living proof that what they found does work. I can wait to finish reading it.</div><div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; "> </div><div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; ">Rgds,</div><div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; "> </div><div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; ">JC</div><div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; "> </div><div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; "> </div><div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; "> </div><div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; ">In a message dated 10/29/2009 7:40:33 P.M. Eastern Standard Time,<span class="Apple-converted-space"> </span><a href="mailto:Dia-@pkdiet.com">Dia-@pkdiet.com</a><span class="Apple-converted-space"> </span>writes:</div><blockquote style="padding-left: 5px; margin-left: 5px; border-left-color: blue; border-left-width: 2px; border-left-style: solid; "><font face="Arial" color="#000000" size="2" style="background-color: transparent; "><br>I understand what you are saying JC. Many many years ago, in my hippy days, I traveled extensively throughout Asia, it was so sad to meet up with fellow travelers later after they had become addicted to opium or heroin. They were like walking skeletons.<div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; "><br></div><div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; ">Opiates happen to be something I cannot take. I just throw up and cannot keep it down. Following my liver resection surgery the docs got very creative on what to give me to relieve pain. </div><div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; "><br></div><div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; ">There are several with PKD who have written to me that the only way they can function is by taking opiates to control the daily chronic pain from PKD. </div><div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; "><br></div><div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; ">By removing a cystic PKD kidney this has been shown to lessen painful episodes. A very observant surgeon developed a denervation procedure of PKD kidneys as another treatment to lessen severe PKD pain.</div><div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; "><br></div><div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; ">There is a PKD pain study underway at the Mayo Clinic with Dr. Marie Hogan that utilizes an interventional procedure known as - Videothracoscopic Splanchnicectomy (VSPL) similar to Videothoracoscopic splanchnicectomy done for pancreatitis pain. For more information on this clinical trial :</div><div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; "><br></div><div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; "><a href="http://www.pkdiet.com/pages/pain/painchronic.htm">http://www.pkdiet.com/pages/pain/painchronic.htm</a></div><div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; "><br></div><div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; ">I too did not realize how difficult and how severe PKD pain can become with some individuals until I went to PKD conference and met with a few individuals using fentanyl patches and more to function. </div><div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; "><br></div><div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; "><font class="Apple-style-span" size="3"><span class="Apple-style-span" style="font-size: 12px; "><i>"FDA announced on February 12, 2008, that PriCara, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.has recalled all lots of 25 mcg DURAGESIC® (fentanyl transdermal system) patches sold by PriCara in the United States and all 25 mcg/hr fentanyl patches sold by Sandoz Inc.(See:Sandoz Fentanyl Patch Recall) in the United States are being voluntarily recalled."</i></span></font></div><div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; "><br></div><div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; "><br></div><div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; ">At this same PKD conference there was a PKD pain lecture given by both Dr. Torres [giving the medical aspects of PKD pain relief] and the laparoscopic surgeon who developed the denervation procedure. I always learn so much from these conferences, though I have not gone to one since Dr. Torres stopped going.</div><div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; "><br></div><div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; ">Warmly,</div><div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; ">Diane</div><div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; "><span><Diane1.jpg></span><br> <br><div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; "><div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; ">On Oct 29, 2009, at 12:23 PM,<span class="Apple-converted-space"> </span><a title="mailto:jcro-@aol.com" href="mailto:jcro-@aol.com" target="_blank" rel="nofollow" ymailto="mailto:jcro-@aol.com">jcro-@aol.com</a><span class="Apple-converted-space"> </span>wrote:</div><br class="Apple-interchange-newline"><blockquote type="cite"><div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; font-size: 10pt; color: rgb(0, 0, 0); font-family: Arial; "><font face="Arial" color="#000000" size="2"><div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; "><div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; ">I refused to take Opiates at all cost. Part of my work is working with drug addicted patients and I have seen what Opiates do to a persons life. It literally destroys them physically, financially, mentally and emotionally to the point that they can not function. It is very sad. Do not take them if you can help it. They are extremely addictive.</div><div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; "> </div><div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; ">Rgds,</div><div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; "> </div><div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; ">JC</div><div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; "> </div><div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; "> </div><div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; "> </div><div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; "> </div><div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; ">In a message dated 10/29/2009 2:40:55 P.M. Eastern Daylight Time,<span class="Apple-converted-space"> </span><a title="mailto:Dia-@pkdiet.com" href="mailto:Dia-@pkdiet.com" target="_blank" rel="nofollow" ymailto="mailto:Dia-@pkdiet.com">Dia-@pkdiet.com</a><span class="Apple-converted-space"> </span>writes:</div><blockquote style="padding-left: 5px; margin-left: 5px; border-left-color: blue; border-left-width: 2px; border-left-style: solid; "><font face="Arial" color="#000000" size="2" style="background-color: transparent; ">Some members have chronic pain from PLD and take opiods which can lead to constipation. Here is a new drug to ask your docs about if this applys to you.<div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; "><br></div><div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; "><span class="Apple-style-span" style="font-size: 11px; font-family: Arial, Helvetica, sans-serif; "><table cellspacing="0" cellpadding="0" width="500" align="center" border="0"><tbody><tr><td valign="top" height="40" style="font-weight: bold; font-size: 17px; color: rgb(0, 51, 153); font-family: georgia; "><h1 style="font-weight: bold; font-size: 19px; color: rgb(0, 51, 153); font-family: georgia; ">ACG: Compound Eases Constipation for Opioid Patients</h1></td></tr><tr><td height="40" style="border-top-color: rgb(204, 204, 204); border-top-width: 1px; border-top-style: solid; font-size: 11px; border-bottom-color: rgb(204, 204, 204); border-bottom-width: 1px; border-bottom-style: solid; "><div id="pageContent" style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; display: block; "><table border="0"><tbody><tr><td style="font-size: 11px; "><table border="0"><tbody><tr><td style="padding-right: 0px; padding-left: 0px; font-size: 11px; padding-bottom: 5px; padding-top: 5px; "><span style="font-size: 11px; color: rgb(0, 0, 0); font-family: arial; ">By Kristina Fiore, Staff Writer, MedPage Today<br><span style="color: rgb(102, 102, 102); ">Published: October 28, 2009</span><br>Reviewed by <a class="tbhdln" title="http://www.medpagetoday.com/reviewer.cfm?reviewerid=30" href="http://www.medpagetoday.com/reviewer.cfm?reviewerid=30" target="_blank" rel="nofollow" style="font-size: 12px; color: rgb(0, 0, 153); text-decoration: none; ">Zalman S. Agus, MD</a>; Emeritus Professor <br>University of Pennsylvania School of Medicine and<br>Dorothy Caputo, MA, RN, BC-ADM, CDE, Nurse Planner</span></td><td align="right" style="font-size: 11px; padding-top: 5px; "><a title="http://www.medpagetoday.com/posttest.cfm?testpage=16658&TBID=16658&topicid=315" href="http://www.medpagetoday.com/posttest.cfm?testpage=16658&TBID=16658&topicid=315" target="_blank" rel="nofollow" style="font-size: 12px; color: rgb(0, 0, 153); text-decoration: none; "></a><br></td></tr></tbody></table></td></tr><tr><td style="font-size: 11px; padding-top: 10px; "><span style="font-size: 12px; line-height: 15px; font-family: arial; "><table width="120" align="right" border="0"><tbody><tr><td valign="top" align="right" style="font-size: 11px; "><span><16658.jpg></span></td></tr></tbody></table><div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; font: normal normal normal 12px/normal Arial; color: rgb(21, 21, 21); ">SAN DIEGO -- An investigational drug increased spontaneous bowel movements for patients with opioid-induced constipation, researchers said here.<br><br>Bowel movements per week increased from about one at baseline to five or six, depending on the dose used, Lynn Webster, MD, of Lifetree Clinical Research in Salt Lake City, and colleagues reported at the American College of Gastroenterology meeting here.<br><br>The drug, NKTR-118, "increased the frequency of bowel movements without a reversal of analgesia, and it was reasonably safe with no serious problems in this study," Webster said.<div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; line-height: 15px; "><br class="webkit-block-placeholder"></div>He said constipation is a common side effect of opioid therapy, affecting about 40% to 60% of patients on chronic or acute treatments.<div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; line-height: 15px; "><br class="webkit-block-placeholder"></div><p style="line-height: 15px; ">The investigational compound is a polymer form of naloxone that antag onizes peripheral opioid receptors in the gut. It can act selectively, preventing it from reversing opioid pain management, the researchers said.</p><p style="line-height: 15px; ">For their Phase-II, randomized, double-blind, placebo-controlled trial, the researchers recruited patients on stable regimens of opioids who consistently had fewer than three spontaneous bowel movements per week.</p><p style="line-height: 15px; ">A total of 208 patients were randomized to either a 5-mg, 25-mg, or 50-mg dose of NKTR-118 or placebo for four weeks.</p><p style="line-height: 15px; ">The researchers found that spontaneous bowel movements increased significantly for patients on the 25-mg and 50-mg dose compared with placebo.</p><p style="line-height: 15px; ">Patients on the 25-mg dose increased to five spontaneous bowel movements per week, up from 1.4 per week at baseline, whereas placebo patients increased to just 3.1 per week from 1.2 at baseline.</p><p style="line-height: 15px; ">Those on the 50-mg dose had six spontaneous bowel movements per week, up from 1.6 at baseline -- a significant improvement compared with those on placebo, who increased to 3.3 per week from 1.4 at baseline.</p><p style="line-height: 15px; ">Spontaneous bowel movements for patients on the 5-mg dose did not differ significantly from those on placebo, the researchers said.</p><p style="line-height: 15px; ">The median time to first bowel movement was 6.6 hours for those in the 25-mg dose, compared with 48.6 hours for those on placebo (<em>P</em>=0.001). It was 2.9 hours for those on the 50-mg dose, compared with 44.9 hours with placebo (<em>P</em>=0.002).</p><p style="line-height: 15px; ">Webster said that there was no change in patient pain, and there were no changes in the amount of opioid used for any patient.</p><p style="line-height: 15px; ">However, dropout rates were significantly higher for the 50-mg dose of the drug compared with placebo, "probably due to the side effect profile," Webster said.</p><p style="line-height: 15px; ">The most sign ificant side effects associated with the drug were gastrointestinal in nature, and included nausea and abdominal pain.</p><p style="line-height: 15px; ">Side effects were not significantly different for the 5-mg dose compared with placebo, and there was more nausea in the placebo group for the 25-mg dose, but side effects were significantly higher in the 50-mg dose compared with placebo.</p><p style="line-height: 15px; ">There was also one serious adverse event in the 50-mg dose, with a patient admitted to the hospital for excessive abdominal cramping.</p></div></span></td></tr></tbody></table></div></td></tr></tbody></table></span></div><div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; "><br></div></font></blockquote></div><div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; "></div><div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; "> </div></font></div></blockquote></div><br></div></font></blockquote></div><div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; "></div><div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; "> </div></font></div></div></div><br></div></blockquote></div><br></div></body></html>
--Apple-Mail-80--184793828
Content-Transfer-Encoding: base64
Content-Disposition: inline;
filename="japanes cucumber.jpg"
Content-Type: image/jpg;
x-mac-type=4A504547;
x-mac-creator=3842494D;
x-unix-mode=0644;
name="japanes cucumber.jpg"
Content-Id: <4C0F4049-ABDD-44D2-@hawaii.rr.com>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--Apple-Mail-80--184793828--
--Apple-Mail-79--184793828--
|
|
 |
|
